Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months

Table 2 Factors influencing the occurrence of an MS relapse for the first 48 months of fingolimod treatment (efficacy set, N = 237)

Parameter	Unit	p-value	Odds ratio (Wald 95% CI) estimate for being "relapse free"
Age at baseline, years	10.0	0.0372	1.467 (1.023; 2.104)
EDSS score at baseline	1.0	0.0335	0.765 (0.598; 0.979)
Number of relapses during the year before the start of fingolimod treatment	1.0	0.7551	1.088 (0.641; 1.845)
Number of relapses during the 2 years before the start of fingolimod treatment	1.0	0.0452	0.680 (0.467; 0.992)
Severity of the last relapse before the start of fingolimod treatment	1.0	0.4669	0.829 (0.500; 1.374)
Disease duration (days)	1.0	0.1720	1.000 (1.000; 1.000)
Type of previous MS therapy^a
Group 2 vs Group 1	1.0	0.5451	0.787 (0.337; 1.835)
Group 3 vs Group 1	1.0	0.6987	1.015 (0.506; 2.035)

Rows indicated in bold format show statistically significant data. Duration of the diagnosis was calculated as the difference between the date of starting fingolimod treatment and the date of diagnosis
CI Confidence interval, EDSS Expanded Disability Status Scale, MS Multiple sclerosis, N Number of patients
^aPatients were categorized into three groups according to the type of the previous therapy of MS: Group 1 – patients treated with any interferon or glatiramer acetate; Group 2 – patients treated with natalizumab in a period of at least 3 months before initiating fingolimod treatment; Group 3 – patients treated with another medication in addition to the medications stated above

ISSN: 1471-2377